Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Clesrovimab by Merck for Respiratory Syncytial Virus (RSV) Infections: Likelihood of Approval
Clesrovimab is under clinical development by Merck and currently in Phase III for Respiratory Syncytial Virus (RSV) Infections. According to...
Data Insights
Risk adjusted net present value: What is the current valuation of Merck's Clesrovimab?
Clesrovimab is a monoclonal antibody commercialized by Merck, with a leading Phase III program in Respiratory Syncytial Virus (RSV) Infections....